You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

39 Results
Guidelines and Advice
Status: Archived
ID: 4-6b
Aug 2004
Guidelines and Advice
Statistical Reports
Drug
Other Name(s): Akeega™
Jul 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Drug
Other Name(s): Tecentriq® SC
Jul 2025
Drug
Other Name(s): Tecentriq™
Jul 2025
Drug
Other Name(s): Tasigna®
Jul 2025
Drug
Other Name(s): Cytosar®
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
Exceptional Access Program
    midostaurin - First-line treatment of adult patients diagnosed with FLT3-mutated acute myeloid leukemia, in combination with specific standard induction followed by consolidation chemotherapy, according to clinical criteria
Jul 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Jul 2025

Pages